The relevance of alternative RNA splicing to pharmacogenomics

Trends in Biotechnology

Volumn 21, Issue 8, 2003, Pages 346-353

  Bracco, Laurent ^a   Kearsey, Jonathan ^a  

^a ExonHit Therapeutics   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENES; PHARMACODYNAMICS; RNA;

PHARMACOGENOMICS;

BIOTECHNOLOGY;

ACLARUBICIN; AMPA RECEPTOR; ANDROGEN; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CLOZAPINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEOXYCYTIDINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; FUROSEMIDE; GLUCOCORTICOID; GLUTAMIC ACID; HALOPERIDOL; METABOTROPIC RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE; SEROTONIN;

DRUG DEVELOPMENT;

ALTERNATIVE RNA SPLICING; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COLON CARCINOMA; DNA MICROARRAY; DRUG METABOLISM; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; INFLAMMATION; NEUROLOGY; PAIN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RNA ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CARCINOMA;

EID: 0142134358     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(03)00146-X     Document Type: Review

References (87)

1. Murphy M.P., et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics. 10:2000;583-590.
2. Griffin J.P. The cost of adverse drug reactions. Adverse Drug React. Toxicol. Rev. 16:1997;75-78.
3. Lazarou J., et al. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279:1998;1200-1205.
4. Lopez A.J. Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu. Rev. Genet. 32:1998;279-305.
5. Fairbrother W.G., et al. Predictive identification of exonic splicing enhancers in human genes. Science. 297:2002;1007-1013.
6. van der Houven van Oordt W., et al. The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J. Cell Biol. 149:2000;307-316.
7. Matter N., et al. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature. 420:2002;691-695.
8. Grzybowska E.A., et al. Regulatory functions of 3′UTRs. Biochem. Biophys. Res. Commun. 288:2001;291-295.
9. Munoz-Sanjuan I., et al. Isoform diversity among fibroblast growth factor homologous factors is generated by alternative promoter usage and differential splicing. J. Biol. Chem. 275:2000;2589-2597.
10. Faustino N.A., et al. Pre-mRNA splicing and human disease. Genes Dev. 17:2003;419-437.
11. Modrek B., et al. A genomic view of alternative splicing. Nat. Genet. 30:2002;13-19.
12. Misteli T. Different site, different splice. Nat. Cell Biol. 2:2000;E98-E100.
13. Uematsu F., et al. Ligand binding properties of binary complexes of heparin and immunoglobulin-like modules of FGF receptor 2. Biochem. Biophys. Res. Commun. 272:2000;830-836.
14. Naimi B., et al. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate. 52:2002;245-252.
15. De Moerlooze L., et al. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development. 127:2000;483-492.
16. Eswarakumar V.P., et al. The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development. 129:2002;3783-3793.
17. Wollerton M.C., et al. Differential alternative splicing activity of isoforms of polypyrimidine tract binding protein (PTB). RNA. 7:2001;819-832.
18. Krawczak M., et al. Human gene mutation database - a biomedical information and research resource. Hum. Mutat. 15:2000;45-51.
19. Cartegni L., et al. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3:2002;285-298.
20. Ars E., et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet. 9:2000;237-247.
21. Teraoka S.N., et al. Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am. J. Hum. Genet. 64:1999;1617-1631.
22. Einstein R. Splicing 2002: RNA splicing in human pathology. Pharmacogenomics. 4:2003;19-22.
23. Stoilov P., et al. Defects in pre-mRNA processing as causes of and predisposition to diseases. DNA Cell Biol. 21:2002;803-818.
24. Nelson D.R., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
25. Hanioka N., et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934 - A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Hum. Genet. 47:1990;994-1001.
26. Woo S.I., et al. Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders. Neurology. 53:1999;1570-1572.
27. Huang Z., et al. Alternative splicing of CYP2D mRNA in human breast tissue. Arch. Biochem. Biophys. 343:1997;101-108.
28. Finta C., et al. Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. 277:2002;5882-5890.
29. Christmas P., et al. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J. Biol. Chem. 276:2001;38166-38172.
30. Johansson M., et al. Human deoxycytidine kinase is located in the cell nucleus. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11941-11945.
31. Eriksson S., et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv. Enzyme Regul. 34:1994;13-25.
32. Veuger M.J., et al. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood. 99:2002;1373-1380.
33. Obata T., et al. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn. J. Cancer Res. 92:2001;793-798.
34. Raida M., et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res. 7:2001;2832-2839.
35. Johnson M.R., et al. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8:2002;768-774.
36. Mercatante D., et al. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol. Ther. 85:2000;237-243.
37. Mercatante D.R., et al. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochim. Biophys. Acta. 1587:2002;126-132.
38. Gimenez I., et al. Spatially distributed alternative splice variants of the renal Na-K-Cl cotransporter exhibit dramatically different affinities for the transported ions. J. Biol. Chem. 277:2002;8767-8770.
39. Sugimura K., et al. Alternative splicing of the mRNA coding for the human endothelial angiotensin-converting enzyme: a new mechanism for solubilization. Biochem. Biophys. Res. Commun. 247:1998;466-472.
40. Grabowski P.J., et al. Alternative RNA splicing in the nervous system. Prog. Neurobiol. 65:2001;289-308.
41. Schmucker D., et al. Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell. 101:2000;671-684.
42. Chandrasekharan N.V., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13926-13931.
43. Xu R., et al. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol. Psychiatry. 7:2002;1075-1082.
44. Centonze D., et al. Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology. 27:2002;723-726.
45. Wu H.E., et al. Spinal pretreatment with antisense oligodeoxynucleotides against exon- 1, -4, or -8 of mu-opioid receptor clone leads to differential loss of spinal endomorphin-1-and endomorphin-2-induced antinociception in the mouse. J. Pharmacol. Exp. Ther. 303:2002;867-873.
46. Koch T., et al. C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization. J. Biol. Chem. 276:2001;31408-31414.
47. Rosa M.L., et al. Expression of mRNAs encoding flip isoforms of GluR1 and GluR2 glutamate receptors is increased in rat hippocampus in epilepsy induced by tetanus toxin. Epilepsy Res. 36:1999;243-251.
48. Tomiyama M., et al. Flip and flop splice variants of AMPA receptor subunits in the spinal cord of amyotrophic lateral sclerosis. Synapse. 45:2002;245-249.
49. Sommer B., et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science. 249:1990;1580-1585.
50. Partin K.M., et al. Structural determinants of allosteric regulation in alternatively spliced AMPA receptors. Neuron. 14:1995;833-843.
51. Flor P.J., et al. The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists. J. Neurochem. 67:1996;58-63.
52. Pindon A., et al. Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins. Mol. Pharmacol. 61:2002;85-96.
53. Claeysen S., et al. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol. 55:1999;910-920.
54. Stephens J.C. Single-nucleotide polymorphisms, haplotypes, and their relevance to pharmacogenetics. Mol. Diagn. 4:1999;309-317.
55. Alderton W.K., et al. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357:2001;593-615.
56. Stangl K., et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics. 10:2000;133-140.
57. Golub T.R., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537.
58. van't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
59. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
60. Black D.L. Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell. 103:2000;367-370.
61. Shoemaker D.D., et al. Experimental annotation of the human genome using microarray technology. Nature. 409:2001;922-927.
62. Hu G.K., et al. Predicting splice variant from DNA chip expression data. Genome Res. 11:2001;1237-1245.
63. Schweighoffer F., et al. Qualitative gene profiling: a novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity. Pharmacogenomics. 1:2000;187-197.
64. Tsujimoto Y., et al. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. U. S. A. 83:1986;5214-5218.
65. Minn A.J., et al. Bcl-x(S) antagonizes the protective effects of Bcl-x(L). J. Biol. Chem. 271:1996;6306-6312.
66. Kuhl J.S., et al. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. Br. J. Cancer. 75:1997;268-274.
67. Zhou M., et al. A novel splice variant of the cell death-promoting protein BAX. J. Biol. Chem. 273:1998;11930-11936.
68. O'Connor L., et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17:1998;384-395.
69. Guo B., et al. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J. Biol. Chem. 276:2001;2780-2785.
70. Bae J., et al. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275:2000;25255-25261.
71. Bingle C.D., et al. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J. Biol. Chem. 275:2000;22136-22146.
72. Himeji D., et al. Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood. 99:2002;4070-4078.
73. Jiang Z.H., et al. Alternative splicing and programmed cell death. Proc. Soc. Exp. Biol. Med. 220:1999;64-72.
74. Lange C., et al. Cloning and initial analysis of the human multidrug-resistance-related MVP/LRP gene promoter. Biochem. Biophys. Res. Commun. 278:2000;125-133.
75. Mahotka C., et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int. J. Cancer. 100:2002;30-36.
76. Whitman S., et al. Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol. Cell. Biol. 20:2000;583-593.
77. Cascino I., et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:1995;2706-2713.
78. Oda K., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:2000;849-862.
79. Koseki T., et al. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. U. S. A. 95:1998;5156-5160.
80. Wu M.X., et al. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 281:1998;998-1001.
81. Caldenhoven E., et al. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271:1996;13221-13227.
82. Wotawa A., et al. Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Lett. 185:2002;181-189.
83. Lai G.J., et al. Opposing actions of adrenal androgens and glucocorticoids on alternative splicing of Slo potassium channels in bovine chromaffin cells. Proc. Natl. Acad. Sci. U. S. A. 99:2002;7722-7727.
84. Andreassi C., et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. 10:2001;2841-2849.
85. Walter H.J., et al. Ethanol regulates calcium channel subunits by protein kinase C delta dependent and independent mechanisms. J. Biol. Chem. 275:2000;25717-25722.
86. Meshul C.K., et al. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem. 67:1996;1965-1973.
87. Willoughby D.A., et al. Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. J. Mol. Neurosci. 6:1995;257-276.